Phase III Trial On Concurrent And Adjuvant Temozolomide Chemotherapy In Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. (RTOG 0834)

Trial Profile

Phase III Trial On Concurrent And Adjuvant Temozolomide Chemotherapy In Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. (RTOG 0834)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
  • Focus Registrational; Therapeutic Use
  • Acronyms CATNON
  • Most Recent Events

    • 10 Aug 2017 Results of the pre-specified interim analysis (n=745; As of 31 May 2015) published in The Lancet
    • 26 Jul 2017 Planned End Date changed from 16 Sep 2015 to 1 Jan 2024.
    • 26 Jul 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top